Pancreatic Transdifferentiation Using β-Cell Transcription Factors for Type 1 Diabetes Treatment.

Mahoney, ALG; Nassif, NT; O'Brien, BA; Simpson, AM

Pancreatic Transdifferentiation Using β-Cell Transcription Factors for Type 1 Diabetes Treatment.

Mahoney, ALG Nassif, NT O'Brien, BA Simpson, AM

Permalink

Publisher:: MDPI
Publication Type:: Journal Article
Citation:: Cells, 2022, 11, (14), pp. 2145
Issue Date:: 2022-07-08

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download full textAdobe PDF (648.3 kB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Mahoney, ALG
dc.contributor.author	Nassif, NT
dc.contributor.author	O'Brien, BA
dc.contributor.author	Simpson, AM
dc.date.accessioned	2023-02-08T04:39:02Z
dc.date.available	2022-07-06
dc.date.available	2023-02-08T04:39:02Z
dc.date.issued	2022-07-08
dc.identifier.citation	Cells, 2022, 11, (14), pp. 2145
dc.identifier.issn	2073-4409
dc.identifier.issn	2073-4409
dc.identifier.uri	http://hdl.handle.net/10453/166005
dc.description.abstract	Type 1 diabetes is a chronic illness in which the native beta (β)-cell population responsible for insulin release has been the subject of autoimmune destruction. This condition requires patients to frequently measure their blood glucose concentration and administer multiple daily exogenous insulin injections accordingly. Current treatments fail to effectively treat the disease without significant side effects, and this has led to the exploration of different approaches for its treatment. Gene therapy and the use of viral vectors has been explored extensively and has been successful in treating a range of diseases. The use of viral vectors to deliver β-cell transcription factors has been researched in the context of type 1 diabetes to induce the pancreatic transdifferentiation of cells to replace the β-cell population destroyed in patients. Studies have used various combinations of pancreatic and β-cell transcription factors in order to induce pancreatic transdifferentiation and have achieved varying levels of success. This review will outline why pancreatic transcription factors have been utilised and how their application can allow the development of insulin-producing cells from non β-cells and potentially act as a cure for type 1 diabetes.
dc.format	Electronic
dc.language	eng
dc.publisher	MDPI
dc.relation.ispartof	Cells
dc.relation.isbasedon	10.3390/cells11142145
dc.rights	info:eu-repo/semantics/openAccess
dc.subject.mesh	Cell Transdifferentiation
dc.subject.mesh	Cellular Reprogramming Techniques
dc.subject.mesh	Diabetes Mellitus, Type 1
dc.subject.mesh	Humans
dc.subject.mesh	Insulin
dc.subject.mesh	Insulin-Secreting Cells
dc.subject.mesh	Transcription Factors
dc.subject.mesh	Humans
dc.subject.mesh	Diabetes Mellitus, Type 1
dc.subject.mesh	Insulin
dc.subject.mesh	Transcription Factors
dc.subject.mesh	Insulin-Secreting Cells
dc.subject.mesh	Cell Transdifferentiation
dc.subject.mesh	Cellular Reprogramming Techniques
dc.subject.mesh	Cell Transdifferentiation
dc.subject.mesh	Cellular Reprogramming Techniques
dc.subject.mesh	Diabetes Mellitus, Type 1
dc.subject.mesh	Humans
dc.subject.mesh	Insulin
dc.subject.mesh	Insulin-Secreting Cells
dc.subject.mesh	Transcription Factors
dc.title	Pancreatic Transdifferentiation Using β-Cell Transcription Factors for Type 1 Diabetes Treatment.
dc.type	Journal Article
utslib.citation.volume	11
utslib.location.activity	Switzerland
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Strength - CHT - Health Technologies
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
pubs.organisational-group	/University of Technology Sydney/Centre for Health Technologies (CHT)
utslib.copyright.status	open_access	*
dc.date.updated	2023-02-08T04:38:53Z
pubs.issue	14
pubs.publication-status	Published online
pubs.volume	11
utslib.citation.issue	14

Abstract:

Type 1 diabetes is a chronic illness in which the native beta (β)-cell population responsible for insulin release has been the subject of autoimmune destruction. This condition requires patients to frequently measure their blood glucose concentration and administer multiple daily exogenous insulin injections accordingly. Current treatments fail to effectively treat the disease without significant side effects, and this has led to the exploration of different approaches for its treatment. Gene therapy and the use of viral vectors has been explored extensively and has been successful in treating a range of diseases. The use of viral vectors to deliver β-cell transcription factors has been researched in the context of type 1 diabetes to induce the pancreatic transdifferentiation of cells to replace the β-cell population destroyed in patients. Studies have used various combinations of pancreatic and β-cell transcription factors in order to induce pancreatic transdifferentiation and have achieved varying levels of success. This review will outline why pancreatic transcription factors have been utilised and how their application can allow the development of insulin-producing cells from non β-cells and potentially act as a cure for type 1 diabetes.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/166005